Cell culture-based transdominant genetic techniques provide new methods for discovering peptide/RNA modulators of cellular pathways. We applied this technology to isolate a peptide inhibitor of human rhinovirus. A green fluorescent protein (GFP)-scaffolded library of cDNA fragments was expressed in HeLa cells from a retroviral vector and screened for inhibitors of rhinovirus-mediated cell killing. A DNA clone, I421, increased cell survival in an HRV14 challenge assay from less than 0.5% to greater than 60%. It encodes a 53-amino-acid C-terminal extension of the GFP scaffold. Particular subclones of Hela cells expressing I421 (exemplified by I421dp3) show a delay in virus production and a 50-fold decrease in viral RNA levels at 6 -8 h postinfection. HRV2, HRV14, and HRV16 show a dramatic decrease in plaque-forming ability on I421dp3 while Coxsackievirus B3 showed a small reduction. Levels of ICAM-1, the receptor for the main rhinovirus serotype, are not altered in I421dp3.
Introduction
There is a pressing need for new antiviral drugs for a variety of viruses, including HIV, HBV, and HCV (Boyer and Marcellin, 2000; De Clercq, 2001; Richman, 2001; Shaw and Locarnini, 2000; Torresi and Locarnini, 2000) . Historically, two general methods have been used to identify lead compounds with antiviral activity. Whole cell screens, in which compounds are assayed for inhibition of virus-mediated cell killing, have led to the identification of a variety of drugs (e.g., enviroxime (DeLong and Reed, 1980) and pleconaril for human rhinovirus and VP32947 (Baginski et al., 2000) for bovine viral diarrhea virus). Alternatively, knowledge of viral protein structure and function has enabled screens for compounds that inhibit specific enzymatic activities (e.g., viral proteases (Patick and Potts, 1998) ) essential for replication. This latter strategy has also been aided by rational design methods based on the crystal structures of viral proteins (e.g., the influenza neuraminidase (Lew et al., 2000) and the rhinovirus protease (Patick et al., 1999) and capsid (Badger et al., 1988) ). A much smaller number of antiviral therapies involve modulating host functions or proteins, for example, interferon treatment for HCV (Taylor, 2000) . Despite an increase in our understanding of the viral-host interactions necessary for the replication of viruses, the number of obvious antiviral targets has remained limited.
Recent developments in the ability to perform functional screens for transdominant factors may provide another strategy for the identification of novel antiviral drug targets and ultimately lead to compounds with new specificities (Kamb and Teng, 2000; Roninson et al., 1995) . These techniques combine aspects of expression cloning with the cycling methods of SELEX or phage display to enrich, from com-plex DNA libraries, those rare molecules that encode peptides or RNAs that confer desired phenotypes; we have termed these transdominant agents "perturbagens"; i.e., factors that perturb a cellular process and thereby induce a selective phenotype.
To date, several successful high complexity, en masse transdominant genetic selections have been executed. From a screen for genetic suppressor elements (GSEs) that confer resistance to the anticancer drug etoposide on mouse cells, Gudkov et al., (1994) reported the identification of three factors including an anti-sense kinesin clone. In the budding yeast, Saccharomyces cerevisiae, three groups independently screened for suppressors of the pheromone response pathway and identified numerous peptide inhibitors of pheromone-induced cell cycle arrest (Caponigro et al., 1998; Geyer and Brent, 2000; Norman et al., 1999) . Blum et al., (2000) isolated two peptide aptamer inhibitors of the thymidylate synthase enzyme in Escherichia coli and five aptamers with bacteriocidal activity. Xu et al. (2001) reported the isolation of peptides that confer resistance to taxol-induced cytotoxicity, while Beger et al. (2001) identified a ribozyme-based regulator of BRCA1 expression. There are also several reports of screens using lower complexity, targeted libraries. Of particular relevance to the present work, Holzmayer and colleagues employed a library derived from random fragments of the HIV genome to identify GSEs (both sense and antisense fragments) with antiviral activity (Dunn et al., 1999) .
In this report, we describe the optimization of a rhinovirus-mediated human cell cytopathic assay suitable for performing a transdominant screen for antiviral agents. Execution of an en masse selection with a high-complexity cDNA library resulted in the isolation of a perturbagen that inhibits the virus' life cycle. Initial characterization of perturbagen-carrying cells infected with HRV suggests that it acts at or before the step of RNA replication. We discuss the utility of perturbagens for identifying antiviral drug targets.
Results

Establishment of a rhinovirus bioassay
Several issues are important for the successful execution of an antiviral perturbagen screen. First, the host cell should be amenable to retroviral transduction and allow high levels of expression of the introduced library. Using flow cytometry and retroviral vectors bearing a constitutive CMVpromoter-driven GFP reporter, we ascertained that the H1 subline of HeLa cells, commonly used for growing HRV, is efficiently transduced by VSV-G pseudotyped retroviruses and that the transduced constructs are strongly expressed (data not shown). Second, H1-HeLa cells are efficiently infected and killed by the HRV14 and the virus can be grown to high titer thus allowing the infection of hundreds of millions of cells at high m.o.i. Third, selection of cells displaying the phenotype of interest is straightforward. Since HRV infection of HeLa cells results in host cell death, isolation of antiviral peptides involves a simple selection for cells resistant to the viral assault. Finally, for maximal enrichment of a perturbagen during each cycle of the selection, the bioassay should be tailored to have a low background (i.e., non-perturbagen-carrying cells do not survive the infection) but concurrently optimized for sensitivity (cells carrying active perturbagens frequently survive the infection). Reinfection by progeny virus at a high, uncontrolled m.o.i., will lower the recovery of weak perturbagens. To suppress this effect we employed two independent strategies specific to rhinovirus: an HRV14 neutralizing antibody (mAb17) and heat shock. Specifically, mAb17 was added 4 h after the HRV infection while the shift in temperature from 33 to 39°C occurred about 24 h postinfection (see Materials and Methods). With both blocks in place, we titrated the HRV m.o.i. to reproducibly achieve survival frequencies between 1/100 and 1/1500 in our assay at 48 h postinfection.
Selection for HRV resistance
Using the optimized bioassay, we executed a selection for transdominant agents that conferred rhinovirus resistance (diagrammed in Fig. 1) . A human placental randomprimed cDNA library of 12 ϫ 10 6 complexity was packaged into retrovirus and transduced into HeLa cells. The cDNAs were cloned at the 3Ј end of a nonfluorescent GFP variant (Methods and Fig. 1 ) such that the cloned fragments were expressed as C-terminal extensions of GFP. These transduced cells were infected with HRV14 at an m.o.i. of 10 and then treated with anti-HRV antibodies and heat shock. Cells that survived the HRV14 infection were used as a source for genomic DNA from which to PCR amplify the retroviral cDNA inserts. To enrich for active perturbagens, the recovered cDNA fragments were recloned into the retroviral vector, packaged into retrovirus particles using 293gp cells, and transduced into naïve HeLa cells for another round of selection. This cycling process was iterated until significant HRV14 resistance was conferred by the sublibrary relative to the vector (352.1) control.
Starting with the same initial cDNA library transduced into HeLa cells, two independent HRV14 selections ("A" and "B") were performed in parallel. The difference between the two screens was that the B series involved a more stringent initial round (less than 1/60,000 cells surviving two successive infections with HRV14 compared to 1/1300 survivors for the A series, see Fig. 2 legend for details). The A and B selections followed standard conditions after the first round (see Materials and Methods) . Under these conditions survival of the cells transduced by the vector control (352.1) ranged from 0.1 to 1.0%, occasionally getting as high as 1.5%. As shown in Fig. 2 , the fraction of HeLa cells surviving HRV14 infection changes dramatically over the course of four rounds of selection. Initially, the percentage of surviving cells observed in library-containing populations mirrored the number observed in the control (Fig. 2 , Vector) and was less than 0.1%. By the end of four rounds of cycling, the fraction of HRV14 resistant cells in the sublibrary populations was 1.1% in group A and 6.6% in group B, respectively; this corresponds to a 14-to 426-fold increase in signal over the vector control background, depending upon the sublibrary measured. More important than the fold increase over background (which suffers from the variability in background described above), we observed close to the same absolute signal in independent transductions of a given sublibrary (data not shown).
Throughout the selection process, we investigated the representation of clones within a given sublibrary by sequence analyses. Following each cycle of selection, randomly chosen clones from each sublibrary were isolated and the cDNA fragments were sequenced. Altogether, several hundred clones isolated from the sublibraries prepared from cycles one through three were analyzed and grouped based on sequence identities. Clones that enriched through the series of selections, i.e., those that were present at higher frequencies in the later sublibraries relative to the earlier ones, were repackaged in 293gp cells and tested individually for their ability to block HRV14-mediated cytotoxicity in the HeLa bioassay. Twenty million cells were transduced with the parental library and grown out for 4 days at 33°C. One hundred million cells were infected with HRV14, mAb17 was added at 4 h, and the cells were washed at 24 h. Because cell killing was less than expected, the experiment was split in two. Half of the cells (group A) were allowed to incubate for a period of 5 days before being harvested. Group B cells were washed at 24 h postinfection, reinfected a second time at 48 h, and then harvested at 5 days. The percentage survival of this round is shown as Cycle 0. Five to ten million cells were transduced with sublibraries from the two groups in subsequent rounds of cycling and the HRV14 infection and blocking steps were identical (see Materials and methods).
Characterization of an anti-HRV perturbagen
One particular sequence group, represented by the I421 clone, was found in multiple sublibraries (those prepared from cycles two and three of both series A and B) and was present 28 times out of the 623 clones sequenced. When I421 was reintroduced into HeLa cells and subsequently challenged with HRV14, a substantial fraction of the I421-containing population was resistant to viral-induced cell death (Fig. 3A , I421 compared to Vector). In numerous independent experiments, 20 to 60% of the I421-containing population was virus resistant compared to 0.1 to 0.8% observed in the vector control populations (representative data in Fig. 3A) .
Sequence analysis showed that the I421 perturbagen consisted of a 312-base-pair cDNA fragment of repetitive DNA that coded for a 53-amino-acid peptide fused to the dGFP scaffold ( Fig. 4Fig. 4 ). Based on nucleotide sequence comparisons against Genbank (BLASTN algorithm, (Altschul et al., 1997) ), it appears that I421 is derived from a single copy sequence on chromosome 20 in the human genome (nucleotides 23,490 to 23,800 of Genbank Accession No. AL050326) with no significant similarity to entries in the database of expressed sequence tags (dbEST). The peptide italics. An open-ended box encloses the C-terminal residues of canonical GFP (all but the last amino acid of wild-type GFP are present). The out-of-frame variant of I421 shown in Fig. 3 was constructed by filling in the BsrG I site immediately 5Ј of the Sfi I site depicted to add the four bases GTAC.
encoded by I421 shows a strong bias in amino acid composition; the first half is highly negatively charged (11 Asp and 1 Glu residues out of 27) while the second half is extremely hydrophobic (11 Met, 7 Val, 1 Ile, and 2 Leu out of 26).
To ascertain if the mode of action of the I421 was at the protein or the RNA level, we made and tested an out-offrame version of the perturbagen that should express essentially the same RNA sequence but an alternate peptide fused to the dGFP scaffold (see Fig. 4 legend). In contrast to the original I421 perturbagen, HeLa cells transduced with the out-of-frame construct exhibited no antiviral activity (Fig.  3A , I421-OF). An anti-GFP immunoblot was performed to show that both the in-and out-of-frame constructs of I421, and by inference their mRNAs, were expressed at equivalent levels, indicating that the lack of an effect in the bioassay by the out-of-frame construct was not due to lower expression levels (Fig. 3B ). Taken together, the data support the notion that I421 acts as a peptide rather than as an RNA molecule.
Single-step growth curves
To begin investigating the I421 mechanism of action, single-step virus growth curves were performed on HeLa cells transduced with either the I421 perturbagen or the control vector. Viral titers produced by the different cells during this time course study were quantified by TCID 50 assay. Fig. 5 shows that the burst size from a population of I421-containing HeLa cells infected with HRV14 appeared to be identical to that of comparably infected control cells at all times after infection. This result is consistent with heterogeneity within the I421-transduced population (e.g., due to different cell-to-cell expression levels; see Discussion). If, for example, 50% of the cells survived rhinovirus infection, then the remaining half that succumbed may still produce a normal burst of virus; a two to three fold reduction in viral titer would be less than the measurement error of the TCID 50 assay and thus would not be detectable.
Phenotypes of cloned cell lines expressing I421
To eliminate the source of heterogeneity and to investigate whether heritable differences in virus resistance and/or virus production existed within the I421-containing HeLa population, individual cell clones were isolated, expanded under neomycin selection, and examined for changes in the HRV14 burst size. Analysis of two of the lines I421dp2 and I421dp3 (dp for delayed production) showed that the yields of viral progeny at the 6-and 8-h time points were approximately 50-fold lower than those of parent HeLa cells transduced with either I421 or vector control ( Fig. 5 ), suggesting that one or more stages of virus replication was inhibited and/or delayed in these lines. Of interest, 10 h postinfection, the level of virus produced in the I421dp clones rose to within roughly five fold of control cells, implying that I421 confers a delay and a partial block on virus production.
We next asked whether the delay in viral maturation and reduction in viral burst size in the I421dp lines inhibited plaque formation by HRV14 on these cells. Lawns of I421dp3 or vector transduced cells were infected with increasing amounts of HRV14 and the resulting plaques examined 3 days later (Fig. 6 ). The plaques were more numerous on the vector control than on the I421dp3 cells at every level of virus inoculum. We also tested two other serotypes of rhinovirus, HRV16 and HRV2, as well as the related picornavirus, Coxsackievirus B3. As with HRV14, both HRV16 and HRV2 showed a large decrease in the ability to form plaques on I421dp3 cells compared to the vector control. In contrast the Coxsackievirus showed a modest reduction in plaque-forming ability. These data demonstrated that I421 dramatically reduces the capacity of several different rhinovirus serotypes to productively infect and kill host cells.
To determine the frequency of the dp phenotype among cells transduced with I421, we characterized nine randomly selected, neomycin-resistant sublines of I421-transduced cells for their phenotypes with respect to plaque formation by HRV14. Four of the lines showed the phenotype described for the I421dp3 cells, i.e., no plaque formation. Two of the lines supported plaque formation with wild-type efficiency. These lines showed no detectable expression of GFP (encoded by the scaffold in I421) by Western blot (data not shown) despite the fact that they were resistant to neomycin. Finally, cells from three of the sublines were completely killed in the course of the plaque assay even in the absence of rhinovirus, suggesting that their viability at high density was impaired. By contrast 10 of 10 sublines from cells stably transduced with the 352.1 vector exhibited normal plaque formation and normal growth in the plaque assay. These data suggest that the HRV14 plaque inhibition The cells were washed twice and resuspended in 3-ml aliquots of 0.5 ϫ10 6 cells; this step was defined as t ϭ 0. At the indicated times samples were frozen at Ϫ80°C and titered. Aliquots of the cell and virus mixture before (t ϭ Ϫ30 min) and after the incubation (t ϭ Ϫ5 min) were also titered.
observed in the I421dp clones is not a rare event nor does the retroviral vector alone mediate it.
I421 inhibits HRV plus-strand RNA synthesis
Because I421dp3 cells showed a strong HRV14 resistance phenotype in the plaque assay and a kinetic delay in virus production in the single-step growth curve, these cells were further studied to determine more precisely the step in the virus life cycle that was blocked. We used RNA blot analysis to quantitate the level of viral RNA synthesis in infected cells (Fig. 7) . HRV14 infection of cells transduced with either 352.1 (Vector) or the perturbagen (I421) led to a rapid increase in viral positive-strand RNA up to and including the last time point measured at 16 h postinfection. Because cells were beginning to float off the plate and to lyse by 16 h it was difficult to examined later time points in this assay. As was observed for the viral yield (Fig. 5) , there was no difference in RNA synthesis between the perturbagen and the control pools of transduced cells. In contrast the I421dp3 subline demonstrated a marked reduction at all time points (25-fold at 16 h postinfection). This result explains the low virus yield at the 6-and 8-h time points observed in the single-step growth curve although it may Fig. 6 . Plaque assay. Two million cells (a pool of 352.1 vector-transduced cells, "V," or the I421 selected clone "dp3," as indicated) were plated in 6-cm dishes in DMEMϩ10% at 33°C. One day later the cells were infected with 25,250, and 2500 pfu of HRV14, HRV16, HRV2, and CoxB3 as indicated in 1.5 ml of DMEMϩ2%. After 1 h, the media was replaced with 4 ml of 1% molten SeaPlaque agarose (FMC) in DMEMϩ2% and the cells were incubated at 33°C for 3 days. Plaques were visualized by fixing the cells in methanol and staining with 0.2% crystal violet in PBS containing 10% formalin. Although Coxsackievirus is often propagated at 37°C, in the assay shown here the cells were grown at 33°C because the I421dp3 phenotype has only been characterized at 33°C. not explain the rise in titer late in infection (Fig. 5, I421dp2 and I421dp3 at 10 -14 h).
I421 does not induce heat shock, depress ICAM1 levels, or alter cell proliferation rates
Given that growth of HeLa cells at elevated temperatures confers resistance to HRV, it is conceivable that the perturbagen I421 induces an antiviral state by inducing a constitutive heat shock response. To investigate this possibility, protein extracts from HeLa cells stably transduced with I421 or the vector control and grown at different temperatures were probed on a Western blot with antibodies that recognize the inducible isoform of HSP 70. Fig. 8 shows that at 33°C the level of HSP70 was the same in both the vector-and the I421-transduced cells and that both populations showed the same increase with temperature. These results suggest that I421 does not induce a constitutive heat shock response.
Another potential mechanism by which I421 confers HRV14 resistance is to reduce the levels of the ICAM1 receptor required for viral entry. To examine this possibility, Hela cells and derivative lines stably transduced with I421 or the vector control were immunostained with either labeled anti-ICAM1 monoclonal antibodies or an isotype control and analyzed by flow cytometry (Fig. 9) . All of the lines expressed similar levels of cell surface ICAM1; specifically the mean relative fluorescence units (RFU) for the different lines were as follows: Hela, 454 RFU; vector, 375 RFU; I421dp3, 502 RFU; I421 pool, 427 RFU (data not shown), compared to the isotype control staining of 7 to 9 RFU for all four lines. This suggests that I421 is not simply blocking HRV infection by lowering the level of the virus's receptor.
Finally, we ascertained that I421 did not affect the growth rate of HeLa cells by monitoring cell growth over a 7-day time course (Fig. 10) . The doubling times at 33°C calculated from this data did not differ significantly among the cells tested were grown for 3 days at the indicated temperature before being harvested. Proteins extracts were fractionated on a polyacrylamide gel and then stained with Coomassie blue or subjected to Western analysis using anti-HSP 70 antibodies. The Coomassie-stained gel serves as a control for equal loading of the protein lysates. (Hela, 45 h; vector, 38 h; I421 pool, 42 h; I421dp3, 41 h). This suggests that I421 is not inhibiting HRV replication by a nonspecific toxic effect on the host cell.
Discussion
Optimizing a selection for antiviral perturbagens
Certain issues are central to all high-complexity, en masse genetic selections from libraries (Irvine et al., 1991; Levitan, 1998; Sandrock et al., 2001a) . Based on a few transdominant selections that have been executed to date, the frequency of active perturbagens within a complex (Ͼ10 6 ) expression library is generally low (at most 1/10 5 to 1/10 6 ) (Beger et al., 2001; Caponigro et al., 1998; Geyer and Brent, 2000; Gudkov et al., 1994; Norman et al., 1999; Xu et al., 2001 ). The anti-HIV GSEs isolated by Dunn et al. (1999) appeared at a much higher frequency (Table 2 of Dunn et al. (1999) suggests an aggregate frequency of ϳ1/6000). This suppports the notion that the (low-complexity) viral genome is enriched for potential dominant negative factors. Further work will determine whether screens using high-complexity libraries (cDNA or peptide) identify targets missed by the viral genome approach.
As with SELEX or phage display screens, the transdominant genetic screen that we have performed to isolate anti-HRV perturbagens required several rounds of selection (cycling) to achieve sufficient enrichment to identify individual molecules conferring the desired activity. To a first approximation, enrichment in a given round of selection is governed by the following equation:
Enrichment ϭ penetrance of perturbagen background of assay .
For example, in the HeLa cell/HRV14 resistance assay of Fig. 3A , I421 displays a signal of about 25% when the background of the assay was 0.3%; thus, the penetrance of I421 under these conditions is roughly 25% (signal minus background). Thus, the approximate enrichment per cycle of selection is 25%/0.3%, or 83-fold. In principle, the lower the background in the selection, the greater the enrichment. However, a very stringent selection in which few nontransduced cells survive may not result in optimal enrichment because the perturbagenexpressing cells may not survive as well due to the harsh conditions. Conversely, a weak selection that allows 100% survival of perturbagen-carrying cells may have high backgrounds of nonspecific survivors; this lowers the effective enrichment. With cytopathic viruses it is not difficult to achieve a low background of surviving cells; infecting host cells at an MOI as low as 7 should, in theory, leave less than one cell in 1000 uninfected by the initial inoculum. The difficulty comes in harvesting the survivors before they become overwhelmed by the extremely high MOI due to progeny virus. This is especially true if an uninfected cell cannot be separated from its productively infected neighbors before they release the progeny virus.
We have utilized two methods to minimize secondary HRV infections during the course of the selection: an HRV14 neutralizing antibody and heat-shock-induced rhinovirus resistance. The monoclonal antibody, mAb17-IA, which binds to the NIm-IA site of the HRV14 capsid, is highly effective in binding rhinovirus and preventing virus infection Sherry et al., 1986 ). The antibody is not toxic to uninfected HeLa cells, even at the highest concentrations tested (data not shown); thus we were able to use an excess of mAb to inhibit secondary infection. As a second independent block, we took advantage of the fact that rhinovirus replication is extremely sensitive to heat shock (Conti et al., 1999; Killington et al., 1977; Stott and Heath, 1970) . HRV abortively infects cells grown at 39°C. The high-temperature block is associated with enhanced degradation of HRV RNA and it appears to reflect induction of the heat shock response per se rather than a temperature-sensitive factor in viral replication (Conti et al., 1999) . We have observed that growth at 39°C also suppresses the cytotoxicity of HRV14 infection (data not shown). Thus, applying a temperature block after the initial round of infection, but before substantial reinfection has occurred, enhanced the survival of cells showing viral resistance. When applying a perturbagen screen to other viruses for which a temperature block is not available, it may be sufficient to use only one blocking step to minimize secondary infections. Alternatively, a combination of antibodies that recognize independent epitopes on the virus or the use of existing antiviral drugs against the virus should control reinfection.
Several different scaffolds, such as E. coli thioredoxin (Blum et al., 2000; Colas et al., 1996) , A. victoria GFP (Caponigro et al., 1998) , and staphylococcal nuclease (Norman et al., 1999) , have been employed for the presentation of a library of transdominant peptides. In the case of enzyme scaffolds like thioredoxin and nuclease, the catalytic activities were inactivated by mutations to render the protein inert. The accepted primary reason for utilizing a scaffold is to increase protein stability; as a fusion to a stable protein, high levels of expression of the transdominant factor may be achieved within a cell. Another advantage offered by the scaffold is the convenience of a tag or readout for detection and purification purposes. Antibodies are readily available as probes for these well-characterized scaffolds. Two basic methods are used to present the transdominant factor on the scaffold: as a conformationally unconstrained peptide on the amino-or carboxy-terminal end of the protein or as a constrained peptide in an internal loop. These two alternatives have, in theory, different advantages (Kamb and Caponigro, 2001) ; both types of scaffolded-peptide libraries have yielded active perturbagens (Caponigro et al., 1998) .
The I421 perturbagen
Although the I421 sequence was isolated from a cDNA library, it encodes a peptide that may not be derived from a native protein. Rather, it is a serendipitous translation product of a genomic contaminant or cDNA. The repetitive nature of its sequence yields a highly charged peptide segment followed by an extremely hydrophobic segment (Fig.  4) . The extent to which either of these domains is necessary or sufficient for antiviral activity will require further study. Picornavirus RNA replication occurs in membrane complexes and infection promotes extensive reorganization and proliferation of cellular membranes (Egger et al., 2000) . Conceivably, the hydrophobic C-terminus of I421 allows it to interfere with some aspect of this process.
The penetrance of I421 in the HeLa/HRV14 resistance bioassay is incomplete; generally 20 -70% of the host cells survive the viral assault. Accumulated evidence suggests that one major reason for this partial penetrance is the variability in expression level of I421 achieved within a given HeLa cell. Consistent with this notion is the fact that two of the nine I421 clonal lines tested that exhibited regular HRV14 plaques, similar to naïve HeLa cells, did not have detectable levels of I421 by immunoblot. Using flow cytometry and a fluorescent enhanced GFP reporter expressed from our standard retroviral vector, we have found that a population of HeLa cells transduced at a single MOI displays a broad range of GFP expression ranging over 2 logs of fluorescence (data not shown). This cell-to-cell variability in expression levels is not specific to the HeLa cell line as it has also been observed in all other cells lines examined (Sandrock et al., 2001b) . Mechanisms that may account for the heterogeneous expression include position effects of the retroviral integration site within a host cell's genome or mutation/methylation of the retroviral vector. We estimate the CMV promoter and GFP-scaffolded perturbagen used in the present work generally allow singlecopy expression within mammalian cells in the 1 M range (Sandrock et al., 2001b) . By comparison the activity of small-molecule antirhinovirus compounds, such as pleconaril (mean IC 50 of ϳ0.03 M (Pevear et al., 1999) ) or AG7088 (mean IC 50 of 0.023 M (Patick et al., 1999 )), appears to be much stronger. However there are at least two differences between these compounds and the perturbagen described here. First, I421 is a "first generation" perturbagen that has not been evolved into a more active molecule. Second, small molecule inhibitors are usually added to the cell culture media and are thus present in a large reservoir outside of the cell. This contrasts with the situation for a perturbagen, in which there is no reservoir for the active molecule other than what is translated in the cell. It is therefore plausible that elevated concentrations of an optimized I421 derivative, or a small molecule which mimics its activity, could cause complete HRV inhibition.
Mechanism of action of I421
An antiviral perturbagen is a RNA, peptide, or protein fragment which, when expressed in cells, inhibits a step in virus replication. In principle a useful perturbagen could inhibit any step up to and including maturation of the virion. Because it is technically more difficult to devise screens that select for inhibition of late steps in the virus life cycle, we have focused in the present work on inhibitors that prevent virus-mediated cell death. The Northern blot revealed that HRV14 RNA replication is severely inhibited in I421dp subclones (Fig. 7) . Combined with the fact that HRV14 is unable to kill all I421-transduced HeLa cells during an infection, the results suggest that I421 may act to block the virus at an early step in its life cycle.
The level of ICAM1, the cell surface receptor for HRV14, is not altered in cells expressing I421 whether as the pool of transductants or as the cellular subclone I421dp3 (Fig. 9 and data not shown). This suggests that I421 does not act by preventing ICAM1 expression, which correlates with the observation that HRV2 is inhibited as strongly by I421 as either HRV14 or HRV16 (Fig. 6) . While HRV14 and HRV16 use the ICAM1 receptor for initial binding to the host cell (Hofer et al., 1994; Staunton et al., 1989; Tomassini et al., 1989) , HRV2 is a member of the minor group of human rhinoviruses, which use the LDL receptor instead (Greve et al., 1989) . Thus I421 appears to act in a receptor-independent fashion. Further work will be necessary to dissect which step between receptor binding and assembly of a functional RNA replication complex is inhibited.
At least two other, more general, mechanisms of virus inhibition should also be considered. I421 may (i) activate the heat shock response, a block particular to rhinovirus, or (ii) activate the interferon response, a more general antiviral mechanism (Goodbourn et al., 2000) . We have examined the possibility of heat shock and find no evidence for the induction of HSP 70 in I421 cells over the normal levels in HeLa cells (Fig. 8) . We have not yet examined the interferon response in I421 cells; however, we note that (a) I421-transduced cells do not show any significant growth or proliferation defects either immediately after transduction or upon long-term, subconfluent passage (Fig. 10) ; (b) there is no evidence that they undergo apoptosis upon infection by rhinovirus; and (c) they do not appear to confer an antiviral state upon cocultured cells (data not shown); i.e., the perturbagen behaves in a cell autonomous fashion. These observations seem inconsistent with the possibility of a strong interferon induction by I421.
I421dp clones
Random clonal lines of I421-transduced cells exhibited several phenotypes. Four of nine lines of HeLa cells stably transduced with I421 did not support plaque formation. In contrast, all of the 10 stable lines of HeLa cells bearing control vector examined were permissive for HRV14 plaque formation. These data support several inferences. Importantly, I421 coding sequences are necessary for the HRVresistance phenotype of these HeLa cells. Furthermore, the frequencies of I421dp lines exhibiting HRV14 plaque inhibition and delayed/reduced viral replication suggest that the observed viral resistance embodied in these clones is not the product of mutations in cellular genes which act either alone or in conjunction with the perturbagen to block HRV-14 growth. It is possible, however, that a common genetic variant in the parental HeLa population acts in concert with I421 to confer elevated levels of viral resistance. The fact that 3 of 9 clonal lines of I421-transduced cells became inviable during the course of high-density growth in the plaque assay is intriguing and warrants further investigation.
Future work
The inability-to-plaque phenotype of I421dp cells opens the way to isolating mutant virus that are resistant to the action of the I421 perturbagen. Sequence analysis, and reconstruction, of such a mutant can often provide valuable information about the mechanism by which the virus overcomes the inhibitory block and therefore about the inhibitory condition itself (Baginski et al., 2000; Heinz and Vance, 1995; Mosser et al., 1994; Sherry and Rueckert, 1985) .
The fundamental strength of the transdominant approach that we have applied to find antiviral perturbagens lies in the genetics. First, libraries of high complexity can be screened en masse in these cell culture assays. Complementary DNA libraries permit identification of proteins, protein fragments, or peptides that possess classical hypermorphic or dominant negative activity. On the other hand, it is relatively simple to generate synthetic peptide libraries of 10 7 -10 9 complexity from random oligonucleotides. Random peptide libraries have the added advantage of being normalized. Second, molecular tools are readily available to retrieve and manipulate perturbagens of interest. Third, the perturbagen (in this case, the I421 peptide) can serve as a probe to identify its cellular target, if it is a protein, by conventional interaction technologies like the yeast two-hybrid assay or biochemical affinity methods combined with mass spectrometry or peptide sequence analyses. Fourth, the bioassay described here has a large dynamic range so it should be possible to mutagenize the coding sequence of I421 to select for variants conferring increased resistance to the virus. Structureactivity relationships (SAR) with I421 can confirm the validity of a target and shed light on its mechanism of action. Once armed with a protein target, one may proceed to identify small molecules that can displace a fluorescently labeled perturbagen from the target (discussed in Kamb and Teng, 2000) and eventually determine if any of those small molecules can confer HRV resistance. Alternatively, one may apply peptidomimetic approaches to I421 to directly develop a therapeutic agent. CRL-1958) were propagated as monolayers in DMEM media (Invitrogen) supplemented with 10% FBS, 2 mM L-glutamine, 1ϫ MEM nonessential amino acids, 1 mM Na pyruvate (DMEMϩ10%). Cultures were grown at 33°C in humidified chambers with 5% CO 2 unless otherwise indicated. When necessary, clones of cell lines were isolated using a Coulter Epics Elite FACS to sort single cells into a 96-well microplate. Human rhinovirus serotypes 2, 14, and 16 and Coxsackievirus B3 (HRV2, HRV14, HRV16, and Cox B3) were obtained from the American Tissue Culture Collection (ATCC VR-482, respectively) . To obtain virus stocks, subconfluent cultures of HeLa cells were infected with HRV14 virus in DMEM containing 2% serum (DMEMϩ2%) and harvested after Ͼ95% cell death was observed (ϳ3-7 days). Cells and media were collected, frozen and thawed three times at Ϫ80°C, and centrifuged at 1200g to remove debris. Virus preparations were stored at Ϫ80°C in aliquots. Viral stocks were titered by determining the TCID 50 (Reed and Muench, 1938) or by plaque assay.
Materials and methods
Growing cells and virus
H1-HeLa cells (ATCC
Neutralizing HRV14 monoclonal antibody
The hybridoma cell line producing mAb17 (a gift of Tom Smith, Purdue University, West Lafayette, IN) was the source of a HRV14 neutralizing monoclonal antibody (Sherry et al., 1986) . Cells were grown in an Integra Biosciences Cell Line CL-350 Passive Membrane Bioreactor according to the manufacturer's instructions in DMEM media containing 10% FCS, 20 mM HEPES, and 45 nM ␤-mercaptoethanol at 37°C. Every 3 to 4 days, 5 ml of the media was collected, centrifuged at 1200 g, and buffered with 25 mM HEPES, pH 7.5. Pooled mAb17 preparations were then titered for neutralizing activity and frozen at Ϫ80°C in aliquots. Neutralizing titer was determined using a visual readout of virus cytotoxicity in a 96-well microplate. A rhinovirus inhibitory unit (RIU) was defined as the minimal amount of antibody necessary to inhibit cytotoxicity to 1 ϫ 10 4 HeLa cells caused by 2 ϫ 10 5 TCID 50 virus (from a single reference stock of titer 6.3 ϫ 10 6 TCID 50 /ml) at 24 h of infection. After determining the inhibitory titer of one particular reference stock of mAb, other preparations were titered by comparison to this material. Before using the mAb in different experiments it was titered in that assay to determine the plateau region of the survivor versus mAb dose curve.
Detection of dGFP, HSP 70, and ICAM-1
Western blots were performed following standard techniques (Ausubel et al., 2001) . Protein from 10,000 cell equivalents was separated by SDS-PAGE (Novex) and transferred to PVDF membranes (Millipore) using a Novex apparatus. To detect GFP a rabbit polyclonal antibody (Clontech, ) was used at a 1/1000 dilution and the secondary antibody was a HRP-coupled goat anti-rabbit IgG (Boehringer Mannheim, No. 1814141) used at a 1/5000 dilution. To detect HSP 70 the primary antibody was a mouse monoclonal antibody (Santa Cruz Biotechnology, SC-24, 1/500 dilution) and the secondary antibody was a HRP-coupled goat anti-mouse antibody (SC-2005, Santa Cruz, 1/1000 dilution). Bands were visualized with the Amersham ECL detection kit.
Flow cytometry to quantitate cell-surface ICAM-1 (CD54) was performed using R-phycoerythrin-conjugated mouse monoclonal anti-CD54 antibody (BD PharMingen No. 555511) with a mouse monoclonal IgG1 (BD PharMingen No. 555749) as the isotype control. Cells were trypsinized, washed once with PBS, and resuspended at 2 million per ml in PBSϩ10% goat serum. Five microliters of control or anti-CD54 Ab was added to 100 l of cells and incubated for 30 min on ice with occasional mixing. The cells were washed with a 10-fold excess of PBS and resuspended in 400 l of PBS containing 2% formaldehyde. Fluorescence (448-nm argon laser excitation and 575-nm (FL2) emission) was recorded using a Coulter EPICS XL-MCL flow cytometer.
Northern analysis of viral plus-strand RNA synthesis
Total RNA was isolated from infected cells using the RNeasy Mini Kit (Qiagen). Purified RNA was quantitated by OD 260 and equal amounts were fractionated on a 1.0% formaldehyde-agarose gel. The gel was stained with ethidium bromide to judge the integrity of the 16S and 28S ribosomal RNAs and confirm equivalent loading of different samples. The gel was then blotted onto Hybond XL membranes (Amersham-Pharmacia-Biotech), baked at 80°C for 2 h, and incubated for 1 h in hybridization buffer (7% SDS, 1 mM EDTA in 0.5 M Na 2 PO 4 , pH 7.2) (Church and Gilbert, 1984) . A single-stranded radioactive DNA probe complementary to the plus (ϩ) strand of the HRV14 genome was prepared following the protocol of Bednarczuk et al. (1991) , using pWR3.26, which contains a cDNA copy of HRV14 (a gift from WeiMing Lee, UW Madison; (Lee et al., 1993) ), as a template and several primers complementary to the HRV14 plus strand. Radioactive signals were detected and quantitated using a Molecular Dynamics phosphoimager.
Preparation of a human placental cDNA retroviral expression library
Details of the construction of the cDNA library expression library have been described (Richards et al., 2003) .
Briefly, poly(A)
ϩ human placental RNA served as the template for random primed first-strand cDNA synthesis using a primer containing a specific Sfi site (GGCCATTATG-GCC, "SfiA") immediately adjacent to the random 9-mer. A second primer containing a distinct Sfi site (GGCCAG-GCGGCC, "SfiB") adjacent to a 3Ј random 6-mer was used to PCR amplify the cDNA. This was cloned into cognate Sfi sites in the plasmid pVT352.1 which is a pCLBabe/LNCX retroviral vector (a gift of I. Verma, Salk Institute, La Jolla, CA) derived from pLNCX (Miller and Rosman, 1989) . The retrovirus produced from pVT352.1 contains a CMV promoter driving the expression of a nonfluorescent variant of GFP (specifically the mutation Y66F referred to here as dGFP (Poritz et al., 2001) ). The SfiB site is located at the 3Ј end of the dGFP coding sequence (Fig. 4) . The library complexity was approximately 12 ϫ 10 6 clones.
Packaging and transduction of retroviral cDNA libraries and clones
The retroviral infection step is referred to here as a transduction to distinguish it from the subsequent infection with rhinovirus. To generate retrovirus which can transduce the cDNA into HeLa cells the retroviral vector DNA (15 g) was cotransfected with a plasmid expressing the VSV-G envelope protein (10 g of pCMV-VSV.G) into 3 ϫ 10 6 293gp packaging cells (a gift of I. Verma, Salk Institute) per T175 flask using LIPOFECTAMINE (Invitrogen) following the manufacturer's instructions. After 72 h at 37°C the retroviral supernatant was collected, filtered, and frozen at Ϫ80°C. Transduction of the cDNA library or sublibraries derived from the different rounds of selection followed standard procedures (Burns et al., 1993) . In brief, 2 ϫ 10 6 H1-HeLa cells (grown at either 33 or 37°C) were mixed with the retroviral supernatant and plated in a T175 flask at 33°C. In different experiments the ratio of the volume of viral supernatant to total tissue culture media (20 ml DMEMϩ10% containing 6 g/ml polybrene) varied up to 50% vol/vol. After a 24-h incubation, the cells were washed and cultured with fresh media for 2 to 4 more days to allow expression of the genes carried on the transduced retroviral construct. To determine the percentage of cells transduced by a retroviral supernatant (and thus the titer and m.o.i. of the transduction), fixed and permeabilized cells were stained with antibodies recognizing the nonfluorescent GFP scaffold and analyzed by flow cytometry. Over the course of the selection, the titer of the retrovirus stock varied between 3 ϫ 10 5 and 5 ϫ 10 6 transducing particles/ml and the percentage of transduced cells varied between 70 and 99%. From transductions done in parallel at a 1-5% retroviral supernatant the calculated m.o.i. of most large-scale transductions fell between 1 and 4 virus transducing particles per cell (data not shown). In some cases neomycin (500 g/ml Geneticin, Invitrogen) was used to select for the stable integrants; cells were used in virus resistance assays after 10 days of selection and the cells were grown for up to 20 passages before a new stock was thawed for use.
HRV14 survival assay for cycling and measuring virus resistance
HeLa cells, either freshly transduced or after neomycin selection, were grow at 33°C for at least 1 day before infection. Five million cells were plated per T175 flask and simultaneously infected with HRV14 at an m.o.i. of 10 in 20 ml of DMEMϩ2%. In pilot experiments this m.o.i. killed 99 to 99.9% of the control cells in the standard assay. Several procedures were used to minimize secondary infection of the cells by progeny virus of the primary infection. Four hours postinfection, 500 RIU of mAb17 (100 l) was added to the media to inactivate virus released from cells. Twentyfour hours after HRV14 infection the flasks were washed with PBS to remove the floating and loosely adherent dead cells, and DMEMϩ10% containing mAb17 (one-tenth of the original quantity) was added and the cultures were shifted to 39°C. At 48 h postinfection cells were washed with PBS, trypsinized, and counted either by hemacytometer or by scanning the cells for 1 min on a Coulter Epics flow cytometer running at high flow rate. To determine the percentage survivors in the assay, cells containing the same retroviral construct (plated at one-quarter to one-half the density of the infected sample) were mock infected and then treated identically. Some assays of individual retroviral clones were performed in six-well Falcon Multiwell plates with volumes scaled accordingly.
Preparation of sublibraries after HRV infection
To generate a perturbagen sublibrary, cells adhering at the end of 48 h of exposure to HRV were trypsinized and used to prepare genomic DNA (Trizol reagent, Invitrogen). The integrated retroviral inserts were then recovered by two stages of PCR amplification using oligonucleotides with homology to sequences flanking the cDNA insertion site (oVT181: 5Ј-GGATCACTCTCGGCATGGACGAG and oVT178: 5Ј-ATTTTATCGATGTTAGCTTGGCCATT). Specifically, genomic DNA from 10,000 to 700,000 cells was added to a 100-l PCR containing 2.5 mM MgSO 4 , 1.0 M primers, 0.2 mM dNTPs, 100 g/ml BSA, and 10 units HiFi Taq DNA polymerase (Invitrogen) in 1 ϫ buffer supplied by the manufacturer. The mixture was denatured at 94°C for 5 min and then subjected to 20 cycles of 94°C for 15 s; 68°C for 140 s; followed by 68°C for 5 min. Ten microliters of this primary reaction was used to seed a secondary 200-l PCR mix and subjected to a cycle titration under the same conditions (being sampled every 2 cycles from 10 to 20 cycles). The cycle number that first produces visible product on an ethidium bromide stained agarose gel was used in a new 200-l reaction under the same conditions. PCR products were purified by phenol/chloroform extraction and ethanol precipitation before being digested with SfiI (New England Biolabs), purified through a Chroma Spin 200 column (Clontech), and directionally ligated (T4 ligase, Boehinger Mannheim) into pVT352.1 vector that had been cut with SfiI and purified by agarose gel electrophoresis. This DNA was electroporated into DH10B (Electromax, Invitrogen) and selected on LB-Amp plates. Colonies were scraped from the plate and plasmid DNA was purified using a Qiagen kit. To maximize the chance of recovering rare clones we scaled the ligation and transformation to generate at least 10-fold more E. coli colonies than the number of HeLa cells recovered from the selection.
